logo

For the Inventor, By the Inventor

Shiraoka, Japan

Mitsuaki Sakashita

This inventor holds 18 USPTO granted patents, primarily in Mevalonolactone Compounds. Top assignees: Nissan Chemical Industries Limited, Kowa Company Limited. Active years: 1986-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mitsuaki Sakashita. Retrieved from https://idiyas.com/inventor/mitsuaki-sakashita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 180(Granted Patents)


Location History:

  • Urawa, JP (1986 - 1988)
  • Saitama, JP (1991)
  • Shiroaoka, JP (1991)
  • Shitaoka, JP (1991)
  • Shiraoka, JP (1990 - 1993)
  • Saitama-ken, JP (1998)
  • Shiraoka-machi, JP (1999 - 2000)

Company Filing History:

goldMedal18 out of 1,235 
 
Nissan Chemical Industries Limited
 patents
silverMedal1 out of 605 
 
Kowa Company Limited
 patents
where one patent can have more than one assignee

Years Active: 1986-2000

Loading Chart...
Areas of Expertise:
Atherosclerosis
Mevalonolactones
Hyperlipidemia
Quinoline Compounds
Pyrazolopyrimidine
Thienopyridine
Pyrimidine
Pharmaceuticals
Intimal Thickening
Antiatherosclerotic Agents
Cyclic Fused Compounds
Lipids
18 patents (USPTO):Explore Patents
1. 6162798 - Inhibitor of atherosclerotic intimal thickening (2000-12-19),
2. 5872130 - Quinoline type mevalonoactones (1999-02-16),
3. 5856336 - Quinoline type mevalonolactones (1999-01-05),
4. 5854259 - Quinoline type mevalonolactones (1998-12-29),
5. 5185328 - Quinoline type mevalonolactones useful for treating hyperlipidemia, (1993-02-09),
6. 5137891 - 2',3' cyclic fused pyrazolopyrimidine type mevalonolactones (1992-08-11),
7. 5102888 - Quinoline type mevalonolactones useful for treating hyperlipidemia and (1992-04-07),
8. 5055472 - Pyrazolopyrimidine type mevalonolactones (1991-10-08),
9. 5026708 - Pyrimidine type mevalonolactones (1991-06-25),
10. 5026698 - Thienopyridine type mevalonolactones (1991-06-25),
11. 5024999 - Pyrazolopyridine type mevalonolactones useful as pharmaeuticals (1991-06-18),
12. 5011930 - Quinoline type mevalonolactones (1991-04-30),
13. 4977161 - Isoxazolopyridine type mevalonolactones (1990-12-11),
14. 4746663 - Pyrazolo[4,3-d]pyrimidine derivative, process for its production, and (1988-05-24),
15. 4719209 - Antiatherosclerotic agent compositions (1988-01-12),

Title: The Innovations of Mitsuaki Sakashita

Introduction

Mitsuaki Sakashita is a prominent inventor based in Shiraoka, Japan. He has made significant contributions to the field of pharmaceuticals and chemical compounds, holding a total of 18 patents. His work focuses on developing innovative solutions to complex health issues.

Latest Patents

Among his latest patents, Sakashita has developed an inhibitor of atherosclerotic intimal thickening. This compound contains an effective amount of a specific formula that targets the underlying mechanisms of atherosclerosis. Additionally, he has created quinoline type mevalonolactones, which are derivatives featuring a quinoline ring, showcasing his expertise in organic chemistry and medicinal applications.

Career Highlights

Sakashita has worked with notable companies such as Nissan Chemical Industries Limited and Kowa Company Limited. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development in the chemical industry.

Collaborations

Throughout his career, Sakashita has collaborated with esteemed colleagues, including Yoshihiro Fujikawa and Mikio Suzuki. These partnerships have fostered a creative environment that has led to numerous advancements in their respective fields.

Conclusion

Mitsuaki Sakashita's innovative work and dedication to research have made him a significant figure in the realm of chemical inventions. His contributions continue to impact the industry and improve health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…